New immune therapy takes aim at Hard-to-Treat lymphomas
NCT ID NCT01333046
First seen Jun 06, 2026 · Last updated Jun 16, 2026 · Updated 3 times
Summary
This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not gone away. Researchers take a patient's own immune cells, train them in a lab to recognize five cancer-specific proteins, and give them back as an infusion. Some adults also receive a drug called azacytidine to help the cells work better. The goal is to see if this approach is safe and can help control the lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.